omeprazole has been researched along with s 1743 in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 129 (58.11) | 29.6817 |
| 2010's | 73 (32.88) | 24.3611 |
| 2020's | 20 (9.01) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, T; Hasselgren, G; Holmberg, J; Jonsson, A; Kylebäck, A; Lind, T; Röhss, K; Rydberg, L | 1 |
| Faulds, D; Spencer, CM | 1 |
| Collins, DW; D'Amico, D; Falk, GW; Hamelin, B; Joelsson, B; Johnson, DA; Kahrilas, PJ; Schmitt, C; Whipple, J | 1 |
| Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M | 1 |
| Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J | 1 |
| Talley, NJ; Thitiphuree, S | 1 |
| Bang, C; Delle, M; Junghard, O; Lauritsen, K; Lind, T; Moum, B; Omland, TM; Schulz, T; Talley, NJ; Tunturi-Hihnala, H | 1 |
| Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE | 1 |
| Robinson, M | 2 |
| Andersson, T; Hassan-Alin, M; Hasselgren, G; Röhss, K; Weidolf, L | 1 |
| Andersson, T; Hassan-Alin, M; Hasselgren, G; Röhss, K | 1 |
| Andersson, T; Bredberg, E; Hassan-Alin, M; Röhss, K | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 2 |
| Bartuzi, Z; Dite, P; Hasselgren, G; Kleczkowski, D; Kryszewski, A; Larkö, A; Rudzinski, J; Tulassay, Z; Wrangstadh, M | 1 |
| Kromer, W | 1 |
| Savarino, V; Scarpignato, C; Tonini, M; Vigneri, S | 2 |
| Kale-Pradhan, PB; Landry, HK; Sypula, WT | 1 |
| Green, J; Higgins, A; Junghard, O; Wahlqvist, P | 2 |
| Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M | 2 |
| Katz, PO; Ramakrishnan, A | 1 |
| Hasselgren, G; Hedenström, H; Röhss, K | 1 |
| Laine, L | 1 |
| Baker, DE | 2 |
| Hedge, DD; Johnson, TJ | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Armstrong, D; Bardhan, KD; Carlsson, RG; Chen, S; Giaffer, M; Green, JR; Hasselgren, GS; O'Kane, KP; Talley, NJ; Venables, TL | 1 |
| Louis, E | 1 |
| Cheer, SM; Faulds, D; Lamb, HM; Prakash, A | 1 |
| Johnson, DA | 1 |
| D'Anna, L; Figura, N; Gatta, L; Holton, J; Miglioli, M; Perna, F; Ricci, C; Vaira, D | 1 |
| Carlsson, E; Lindberg, P; Olbe, L | 1 |
| Kendall, MJ | 1 |
| Dent, J | 2 |
| Andersson, T; Carlsson, E; Fryklund, J; Keeling, D; Lindberg, P; Lundborg, P | 1 |
| Bianchi Porro, G; Pace, F; Pallotta, S | 1 |
| Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES | 1 |
| Hogan, D; Pratha, V; Sachs, G; Shin, JM | 1 |
| Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E | 1 |
| Lee, J; Machado, S; Veldhuyzen Van Zanten, S | 1 |
| Hellström, PM; Vitols, S | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Bästlein, E; Bayerdörffer, E; Buchner, M; Ebert, S; Haferland, C; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M | 1 |
| Balashova, NN; Maev, IV; Shchekina, MI; Viuchnova, ES | 1 |
| Chang, YM; Chuang, CH; Huang, SF; Kao, AW; Kao, YH; Lai, YL; Sheu, BS; Sheu, MJ | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I | 1 |
| Andersson, T | 1 |
| Gisbert, JP; Pajares, JM | 1 |
| Gatta, L; Miglioli, M; Osborn, JF; Perna, F; Ricci, C; Tampieri, A; Vaira, D; Vakil, N | 1 |
| Anagnostopoulos, GK; Arvanitidis, D; Kostopoulos, P; Margantinis, G; Tsiakos, S | 1 |
| Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H | 1 |
| de Korwin, JD; Ducrotté, P; Vallot, T | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Armstrong, D; Bigard, MA; Green, J; Junghard, O; Lauritsen, K; Lind, T; Mössner, J; Moum, B; Talley, NJ; Tunturi-Hihnala, H; Venables, T | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Freston, JW | 1 |
| Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M | 1 |
| Andersson, T; Hassan-Alin, M; Niazi, M; Röhss, K | 1 |
| Orr, WC | 1 |
| Chen, TW; Cheng, HC; Hunag, SF; Kao, AW; Lu, CC; Sheu, BS; Wu, JJ | 1 |
| Ortiz, V; Ponce, J; Velasco, MJ | 1 |
| Chang, FY; Chen, CY; Lai, YL; Lee, SD; Lu, CL; Luo, JC | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bagel-Boithias, S; Chopineau, J; Messaouik, D; Sautou-Miranda, V | 1 |
| Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF | 1 |
| Herszenyi, L; Hritz, I; Molnar, B; Pronai, L; Tulassay, Z | 1 |
| Chen, YH; Li, HY; Wang, H; Wang, WM | 1 |
| Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Calvet, X; Gomollón, F | 1 |
| Hofmann, U; Klotz, U; Schwab, M; Treiber, G | 1 |
| Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G | 1 |
| Hamelin, B; Hwang, C; Lightdale, CJ; Schmitt, C | 2 |
| Dohmen, W; Fuchs, W | 1 |
| Clark, DW; Strandell, J | 1 |
| Fang, JY; Lu, R; Sun, DF; Wang, X | 1 |
| Bästlein, E; Bayerdörffer, E; Hansky, K; Jacobs, E; Kirsch, C; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M | 1 |
| Blume, H; Donath, F; Schug, BS; Warnke, A | 1 |
| Klotz, U | 1 |
| Hultman, Ia; Liljeblad, M; Stenhoff, H | 1 |
| Bakshi, A; Bungay, K; Devlin, JW; Olsen, KM | 1 |
| Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E | 1 |
| Baldassarre, E; Bianchetti, MG; Ferrarini, A; Sagaon, MM | 1 |
| Junghard, O; Wiklund, IK | 1 |
| Cianciolo, G; Comai, G; Feliciangeli, G; Stefoni, S | 1 |
| Fjellman, M; Kilhamn, J; Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Brazowski, J; Czerwionka-Szaflarska, M | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Bastaki, SM; Chandranath, IS; Singh, J | 1 |
| Pai, N; Pai, V | 1 |
| Davies, M; Shakir, SA; Wilton, LV | 1 |
| Andersson, T; Weidolf, L | 1 |
| Armstrong, D; Chen, Y; Hunt, RH; James, C; Lee, E; Leonard, J; Sachs, G; Shin, JM; Tang-Liu, D; Yaghoobi, M | 1 |
| Giannoulis, E; Karamanolis, G; Ladas, SD; Theofanidou, I; Triantafyllou, K; Yiasemidou, M | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Estborn, L; Joelson, S | 1 |
| Caron, J; Durlach, V; François, M; Lévy-Bohbot, N | 1 |
| Aloumanis, V; Ben, M; Chan, P; Kupiec, TC; Patterson, J; Trissel, LA | 1 |
| Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K | 1 |
| Calvet, X; Garcia, P; Gisbert, JP; Vergara, M; Villoria, A | 1 |
| Dragomir, D; Hurduc, V; Plesca, D; Sajin, M; Vandenplas, Y | 1 |
| Leufkens, HG; Martini, N; Sagliocca, L; Tafuri, G; Traversa, G; Trotta, F | 1 |
| Gursoy, O; Memiş, D; Sut, N | 1 |
| Farrell, CP; Gabello, M; Martin, AP; Morgan, M; Mullin, JM; Murray, LJ; Rudolph, DS; Underwood, JC; Valenzano, MC | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Christ, G; Jilma, B; Kreiner, G; Lang, IM; Siller-Matula, JM; Spiel, AO | 1 |
| Brunet, C; Dine, T; Dupin-Spriet, T; Gressier, B; Kambia, NK; Luyckx, M | 1 |
| Mattia, AR; Wilcox, GM | 1 |
| Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F | 1 |
| Zheng, RN | 1 |
| Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
| Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Tsai, YC; Yeh, YC | 1 |
| Hsu, YC; Lin, HJ; Perng, CL; Tsai, JJ | 1 |
| DAS, R; Edwards, SJ; Lind, T; Lundell, L | 1 |
| Saccar, CL | 1 |
| Groeneveld, L; Hoogendoorn, RJ; Kwee, JA | 1 |
| Dobrovol'skiĭ, OV; Kondratenko, SN; Pisarev, VV; Serebrova, SIu; Starodubtsev, AK; Vasilenko, GF | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Cirilli, R; Ferretti, R; Gallinella, B; La Torre, F; Mosca, A; Sanna, ML; Zanitti, L | 1 |
| Börgel, J; Endres, HG; Engelhardt, A; Krüger, JC; Lask, S; Mügge, A; Neubauer, H | 1 |
| Brikova, SI; Bushkova, EV; Kazakova, RV; Onuchina, EV; Peshkov, DV; Poshkaĭte, IA; Rozhanskiĭ, AA; Tsukanov, VV | 1 |
| Azevedo, F; Barros, AM; Baudrier, T; Cadinha, S; Cunha, AP; Morais, P; Mota, A | 1 |
| Cristofari, F; De Francesco, V; Hassan, C; Manes, G; Scaccianoce, G; Zullo, A | 1 |
| Agranat, I; Marom, H | 1 |
| den Hoed, CM; Kuipers, EJ | 1 |
| Grossmann, D; Knoth, H; Kuhlisch, E; Laass, M; Labenz, J; Löbe, S; Madisch, A; Miehlke, S; Morgner, A | 1 |
| Davis, DA; Johnson, JT; Neill, KK | 1 |
| Chandrashekhar, VM; Phadatare, PD | 1 |
| Keating, GM | 1 |
| Hasenfuss, G; Maier, L; Schillinger, W; Schmitto, J; Schotola, H; Schwörer, H; Sohns, C; Sossalla, S; Toischer, K | 1 |
| Illueca, M; Johnson, DA; Monyak, JT; Sharma, P | 1 |
| Babiak, P; Hájíček, J; Kyslík, P; Kyslíková, E; Marešová, H; Palyzová, A; Stěpánek, V; Valešová, R | 1 |
| Boot, H; de Boer, A; Deneer, VH; Harmsze, AM; Heringa, M; le Comte, M; Mol, PG; Schalekamp, T; Verduijn, MM; Verheugt, FW | 1 |
| Yeomans, ND | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
| Htun, WW; Huang, Y; Ko, W; Kwan, J; Kwan, TW | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW | 1 |
| Kwok, CS; Loke, YK | 1 |
| Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
| de Boer, A; le Cessie, S; Maitland-van der Zee, AH; Redekop, WK; Schalekamp, T; van der Meer, FJ; van Schie, RM; Verhoef, TI; Zuurhout, MJ | 1 |
| Ding, J; Fan, D; Gyawali, PC; Liu, L; Liu, N; Wu, K; Yang, Y; Yao, L; Zhang, D; Zhang, H | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T | 1 |
| Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B | 1 |
| Simpson, SE | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Kasugai, K; Kinoshita, Y; Miwa, H | 2 |
| Almebayadh, M; Avril, MF; Carlotti, A; Dupin, N; Goulvestre, C; Le Guern, V; Mouthon, L; Regnier-Rosencher, E | 1 |
| Metz, DC; Shah, P; Singh, MH; Yang, YX | 1 |
| Hatlebakk, JG; Jonasson, C; Tvete, IF | 1 |
| Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH | 1 |
| Baynham, MT; Blankley, RT; Butler, CF; Fisher, K; Leys, D; McLean, KJ; Munro, AW; Peet, C; Rigby, SE; Voice, MW | 1 |
| Agranat, I; Marom, H; Pogodin, S | 1 |
| Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L | 1 |
| Bertino, JS | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Liu, F; Shokrollahi, H | 1 |
| Attwood, SE; Eklund, S; Ell, C; Fiocca, R; Galmiche, JP; Hasselgren, B; Hatlebakk, JG; Jahreskog, M; Långström, G; Lind, T; Lundell, L | 1 |
| Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ | 1 |
| Barocelli, E; Bettini, R; Castrati, L; Colombo, P; Elviri, L; Flammini, L; Rossi, A | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Fossmark, R; Hauso, Ø; Waldum, HL | 1 |
| Alber, H; Amann, A; Beer, B; Hofstaetter, S; Klieber, M; Modak, A; Neururer, M; Oberacher, H | 1 |
| Liu, L; Qi, Q; Wang, R; Wang, S; Zhao, F | 1 |
| Becker, ML; Franken, WP; Karapinar, F; Schalekamp, T; van der Hoeven, RT; Verzijl-Zeegers, R | 1 |
| Asghar, W; Jamali, F; Pittman, E | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Barbeau, G; Bertrand, OF; De Larochellière, R; Déry, JP; Déry, U; Gleeton, O; Harvey, A; Larose, É; Modak, A; Nguyen, CM; Noël, B; Paradis, JM; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L; Roy, M | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Balza, E; Carta, S; Castellani, P; Gattorno, M; Lavieri, R; Piccioli, P; Rubartelli, A; Semino, C | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Badowski, M; Hung, YT; Law, EH; Lee, TA; Sanchez, A; Weems, K | 1 |
| Chang, YC; Hsiao, CJ; Hsiao, PJ; Wu, KL | 1 |
| Klyarytska, I; Kriviy, V; Modak, AS; Rabotyagova, Y; Tsapyak, T | 1 |
| Damanhuri, NS; Kumolosasi, E; Omar, MS | 1 |
| Eklund, S; Lau, J; Lind, T; Persson, T | 1 |
| El-Kimary, EI; Ragab, MAA | 2 |
| Sebastián Domingo, JJ | 1 |
| Bell, R; Dart, AJ; Huxford, KE; Jeffcott, LB; Perkins, NR | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Türkeş, C | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Johansson, E; Karlsson, A; Ludvigsson, JW | 1 |
| Barbeito Castiñeiras, G; Bardán García, B; Belles Medall, D; Blanco Dorado, S; Blanco Hortas, A; Campos-Toimil, M; Carracedo, Á; Fernández-Ferreiro, A; Gómez Márquez, A; Lamas, MJ; Latorre-Pellicer, A; López-Vizcaíno, A; Maroñas Amigo, O; Otero Espinar, F; Pérez Del Molino Bernal, ML; Rodríguez Jato, MT; Zarra Ferro, I | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Diao, A; Hao, Y; Li, Y; Liu, Y; Liu, Z; McKenzie, EA; Tao, L; Wang, D; Zhang, W; Zhao, Q; Zhao, T | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Hancu, G; Kelemen, H; Papp, LA; Tóth, G | 1 |
| Daali, Y; Desmeules, JA; Lenoir, C; Niederer, A; Rollason, V; Samer, CF | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Baars, MD; Broekhuizen, M; Cornette, J; Danser, AHJ; Koch, BCP; Neuman, RI; Nieboer, D; Russcher, H; Saleh, L; Schoenmakers, S; van den Berg, SAA; van den Meiracker, AH; Verhoeven, M; Visser, W | 1 |
| Barbé, F; Buti, M; de Batlle, J; Galván, L; Piñol-Ripoll, G; Torres-Bondia, F | 1 |
| Bardou, M; Ben Ghezala, I; Luu, M | 1 |
| Chen, P; Fan, K; Luo, P; Peng, J; Wang, X; Zhang, Z; Zhu, X | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Calissendorff, J; Falhammar, H; Issa, I; Lindh, JD; Mannheimer, B; Skov, J | 1 |
| da Mota, AD; da Rosa, TF; de Paula, BR; Foletto, VS; Franco, LN; Hörner, R; Marion, SL; Serafin, MB | 1 |
| Denda, M; Goda, M; Hamano, H; Higashionna, T; Ishizawa, K; Lin, TJ; Miyata, K; Nawa, H; Neishi, M; Niimura, T; Yagi, K; Zamami, Y | 1 |
| Häyrynen, S; Kiiski, JI; Niemi, M; Ramste, M; Ritvos, M; Sinisalo, J | 1 |
| Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP | 1 |
65 review(s) available for omeprazole and s 1743
| Article | Year |
|---|---|
Esomeprazole.
Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Helicobacter pylori; Humans; Omeprazole; Stereoisomerism | 2000 |
Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
Topics: Adult; Aged; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Esomeprazole; Esophagitis, Peptic; Female; Half-Life; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2000 |
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
Topics: Animals; Enzyme Inhibitors; Esomeprazole; Humans; Isomerism; Microsomes, Liver; Omeprazole | 2001 |
Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.
Topics: Anti-Ulcer Agents; Area Under Curve; Drug Interactions; Esomeprazole; Half-Life; Humans; Intestinal Absorption; Omeprazole; Stereoisomerism | 2001 |
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Improving opportunities for effective management of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Esophagitis; Gastric Mucosa; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Isomerism; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2001 |
Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
Topics: Anti-Ulcer Agents; Drug Interactions; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Zollinger-Ellison Syndrome | 2001 |
Esomeprazole for acid peptic disorders.
Topics: Absorption; Anti-Ulcer Agents; Clinical Trials as Topic; Esomeprazole; Esophagitis, Peptic; Humans; MEDLINE; Omeprazole; Treatment Outcome | 2002 |
Pharmacologic management of gastroesophageal reflux disease.
Topics: Barrett Esophagus; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Omeprazole; Pregnancy; Pregnancy Complications; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Review article: esomeprazole in the treatment of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors | 2002 |
Esomeprazole: a review of its use in the management of acid-related disorders.
Topics: Databases, Bibliographic; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Esomeprazole magnesium (Nexium).
Topics: Anti-Ulcer Agents; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Treatment Outcome | 2001 |
Esomeprazole: a clinical review.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Helicobacter Infections; Humans; Omeprazole; Stereoisomerism | 2002 |
Esomeprazole: update and clinical review.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Labeling; Enzyme Inhibitors; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors | 2002 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Sulfoxides; Zollinger-Ellison Syndrome | 2003 |
Review of esomeprazole in the treatment of acid disorders.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2003 |
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
Topics: Animals; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2003 |
Review article: esomeprazole--the first proton pump inhibitor to be developed as an isomer.
Topics: Drug Design; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Isomerism; Omeprazole; Proton Pump Inhibitors | 2003 |
Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Topics: Anti-Ulcer Agents; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Pentagastrin; Proton Pump Inhibitors | 2003 |
Review article: initial therapy of reflux disease with esomeprazole.
Topics: Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Gastroesophageal Reflux; Gastroscopy; Humans; Omeprazole; Randomized Controlled Trials as Topic | 2003 |
Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Gastric Acid; Humans; Omeprazole; Proton Pump Inhibitors | 2003 |
On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2002 |
Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Single-isomer drugs: true therapeutic advances.
Topics: Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2004 |
Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Esomeprazole; Gastric Acid; Humans; Liver; Metabolic Clearance Rate; Omeprazole; Parietal Cells, Gastric; Patient Selection; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome | 2004 |
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prognosis; Proton Pump Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Wound Healing | 2004 |
Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Sulfoxides | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
Pharmacokinetic drug interaction profiles of proton pump inhibitors.
Topics: Anti-Ulcer Agents; Cytochrome P-450 CYP2D6; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Omeprazole; Proton Pump Inhibitors | 2006 |
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
[Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
Topics: Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastrointestinal Diseases; Humans; Kidney Transplantation; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Treatment Outcome | 2007 |
[Proton pump inhibitors in developmental period medicine].
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esomeprazole; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer; Zollinger-Ellison Syndrome | 2008 |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2008 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2008 |
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
The pharmacology of esomeprazole and its role in gastric acid related diseases.
Topics: Clinical Trials as Topic; Drug Interactions; Esomeprazole; Gastrointestinal Diseases; Humans; Omeprazole | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
Intravenous esomeprazole: a pharmacoeconomic profile of its use in the prevention of recurrent peptic ulcer bleeding.
Topics: Anti-Ulcer Agents; Esomeprazole; Humans; Injections, Intravenous; Omeprazole; Peptic Ulcer Hemorrhage; Secondary Prevention | 2011 |
[Interaction between clopidogrel and proton pump inhibitors].
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combination; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Risk | 2011 |
Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.
Topics: Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2012 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2015 |
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Publication Bias | 2015 |
Association Between Proton Pump Inhibitors and Microscopic Colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Colitis, Microscopic; Dose-Response Relationship, Drug; Esomeprazole; Humans; Omeprazole; Pantoprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2017 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Recent Analytical Methodologies for the Determination of Omeprazole and/or Its Active Isomer Esomeprazole in Different Matrices: A Critical Review.
Topics: Electrochemical Techniques; Esomeprazole; Isomerism; Omeprazole; Stereoisomerism | 2022 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis; Esomeprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2021 |
An update on drug-drug interactions associated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2022 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine | 2023 |
57 trial(s) available for omeprazole and s 1743
| Article | Year |
|---|---|
Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.
Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Stereoisomerism | 2000 |
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole | 2000 |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Stereoisomerism | 2000 |
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Follow-Up Studies; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Probability; Reference Values; Secondary Prevention; Treatment Outcome | 2001 |
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Endoscopy; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Stereoisomerism; Treatment Outcome | 2001 |
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Isomerism; Male; Middle Aged; Omeprazole; Safety; Treatment Outcome | 2001 |
Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Esomeprazole; Gastric Acid; Gastric Acidity Determination; Gastrointestinal Agents; Humans; Male; Omeprazole; Pentagastrin; Proton Pump Inhibitors; Proton Pumps; Stereoisomerism; Time Factors | 2001 |
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Time Factors; Treatment Outcome | 2001 |
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Tolerance; Esomeprazole; Female; Gastric Juice; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole | 2002 |
Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Humans; Long-Term Care; Male; Middle Aged; Omeprazole; Patient Satisfaction; Probability; Reference Values; Severity of Illness Index; Treatment Outcome | 2002 |
[Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Humans; Male; Omeprazole | 2003 |
One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Sensitivity and Specificity | 2003 |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2003 |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2003 |
[Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
Topics: Adult; Anti-Ulcer Agents; Asthma; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Time Factors; Treatment Outcome | 2003 |
On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Feces; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Reference Values; Single-Blind Method; Treatment Outcome; Urea | 2004 |
Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pilot Projects; Probability; Prospective Studies; Reference Values; Treatment Outcome | 2004 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea | 2004 |
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Gastroscopy; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Esomeprazole; Female; Half-Life; Humans; Male; Omeprazole; Stereoisomerism; Time Factors | 2005 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastric Mucosa; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mixed Function Oxygenases; Omeprazole; Risk | 2005 |
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.
Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Capsules; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Tablets | 2005 |
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Genotype; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2005 |
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Family Practice; Female; Germany; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Recurrence | 2005 |
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole | 2006 |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Rifabutin; Treatment Outcome | 2006 |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2007 |
One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2007 |
Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Severity of Illness Index; Treatment Outcome | 2007 |
Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
Topics: Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Depression, Chemical; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Half-Life; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Microelectrodes; Middle Aged; Omeprazole | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2008 |
A glass of water immediately increases gastric pH in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Esomeprazole; Female; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach; Time Factors; Water | 2008 |
A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Probiotics; Prospective Studies; Proton Pump Inhibitors; Saccharomyces | 2009 |
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomeprazole; Female; Gastric Acidity Determination; Gastric Juice; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection | 2009 |
Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities.
Topics: Aged; Aged, 80 and over; Comorbidity; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Ulcer; Education, Medical, Continuing; Esomeprazole; Female; Follow-Up Studies; Hemostasis, Endoscopic; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Probability; Prospective Studies; Risk Assessment; Secondary Prevention; Severity of Illness Index; Statistics, Nonparametric; Stomach Ulcer; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy; Epinephrine; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Secondary Prevention; Treatment Outcome; Young Adult | 2009 |
[Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].
Topics: Adult; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Omeprazole; Proton Pump Inhibitors; Time Factors; Tissue Distribution | 2009 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Regression Analysis; Stents; Ticlopidine | 2010 |
Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drugs, Generic; Enzyme Inhibitors; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Statistics as Topic; White People; Young Adult | 2011 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Blood Transfusion; Chi-Square Distribution; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Female; Hemostasis, Endoscopic; Humans; Length of Stay; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Risk Factors; Secondary Prevention; Time Factors | 2012 |
[Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-].
Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2013 |
[Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2013 |
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2013 |
Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Healthy Volunteers; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Platelet Aggregation; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2014 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Platelets; Breath Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Humans; Omeprazole; Pantoprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ranitidine; Ticlopidine | 2016 |
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 CYP2C19; Esomeprazole; Female; Gastroesophageal Reflux; Genetic Association Studies; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Pharmacogenetics; Precision Medicine; Proton Pump Inhibitors; Young Adult | 2016 |
Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
Topics: Adult; Biomarkers; Endothelin-1; Esomeprazole; Female; Humans; Infant; Infant, Newborn; Omeprazole; Placenta; Placenta Growth Factor; Pre-Eclampsia; Pregnancy; Proton Pump Inhibitors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
100 other study(ies) available for omeprazole and s 1743
| Article | Year |
|---|---|
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Topics: Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Omeprazole; Proton Pump Inhibitors; United Kingdom | 2002 |
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Support Techniques; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; United Kingdom | 2002 |
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
[Pharma clinics medication of the month. Esomeprazole].
Topics: Cost Control; Drug Costs; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhibitors | 2002 |
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole | 2003 |
Prilosec, nexium and stereoisomers.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Interactions; Esomeprazole; Methylphenidate; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Esomeprazole; Fluorouracil; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Inhibitory Concentration 50; Lymphoma; Melanoma; Mice; Mice, SCID; Microscopy, Confocal; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Transplantation, Heterologous; Vinblastine | 2004 |
[Gastroesophageal reflux disease refractory to esomeprazole].
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2005 |
Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Beverages; Esomeprazole; Intubation, Gastrointestinal; Lansoprazole; Malus; Omeprazole; Particle Size; Polyurethanes; Proton Pump Inhibitors; Rheology; Silicones; Solvents; Water | 2005 |
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Fiber Optic Technology; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Hypopharynx; Lansoprazole; Laryngoscopy; Male; Manometry; Middle Aged; Omeprazole; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2005 |
Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression.
Topics: Adult; Apoptosis; Cell Proliferation; Epithelial Cells; ErbB Receptors; Esomeprazole; Female; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Tumor Suppressor Protein p53 | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.
Topics: Animals; Calibration; Chromatography, Liquid; Dogs; Esomeprazole; Humans; Molecular Structure; Omeprazole; Rats; Reproducibility of Results; Tandem Mass Spectrometry | 2007 |
An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esomeprazole; Female; Humans; Infusions, Parenteral; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Proton Pumps | 2006 |
Severe systemic adverse reaction to proton pump inhibitors in an infant.
Topics: Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Infant; Lung Diseases; Omeprazole; Proton Pump Inhibitors; Respiratory Sounds | 2007 |
The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.
Topics: Aminopyrine; Animals; Anti-Ulcer Agents; Bucladesine; Carbon Isotopes; Dimaprit; Dinoprostone; Esomeprazole; Female; Gastric Acid; Gastric Mucosa; Histamine; Indomethacin; Inhibitory Concentration 50; Male; Omeprazole; Rabbits; Rats; Rats, Wistar; Stomach | 2008 |
Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
Topics: Adverse Drug Reaction Reporting Systems; Cohort Studies; Diarrhea; Drug Monitoring; Dyspepsia; England; Esomeprazole; Esophageal Diseases; Female; Humans; Male; Middle Aged; Omeprazole; Primary Health Care; Product Surveillance, Postmarketing; Proton Pump Inhibitors | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Retrospective Studies; Young Adult | 2008 |
[Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism?].
Topics: Deglutition Disorders; Duodenum; Esomeprazole; Female; Giardiasis; Humans; Hypocalcemia; Hypoparathyroidism; Magnesium Deficiency; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quadriplegia; Vomiting | 2008 |
Physical and chemical stability of esomeprazole sodium solutions.
Topics: Anti-Ulcer Agents; Drug Stability; Drug Storage; Esomeprazole; Glucose; Humans; Isotonic Solutions; Omeprazole; Polyvinyl Chloride; Ringer's Lactate; Sodium Chloride; Solutions; Time Factors | 2008 |
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Utilization Review; Esomeprazole; European Union; Gastroesophageal Reflux; Government Agencies; Humans; Isomerism; Lansoprazole; Multicenter Studies as Topic; Omeprazole; Pediatrics; Proton Pump Inhibitors; United States; United States Food and Drug Administration | 2009 |
Transmucosal gastric leak induced by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Epithelium; Esomeprazole; Gastric Mucosa; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Permeability; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley | 2009 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Color; Drug Incompatibility; Drug Stability; Drug Storage; Esomeprazole; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Nefopam; Omeprazole; Pantoprazole; Pharmaceutical Solutions; Proton Pump Inhibitors; Temperature; Time Factors | 2009 |
Microscopic colitis associated with omeprazole and esomeprazole exposure.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Colitis, Microscopic; Dose-Response Relationship, Drug; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Netherlands; Omeprazole; Patient Satisfaction; Primary Health Care; Proton Pump Inhibitors; Surveys and Questionnaires; Young Adult | 2009 |
Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate.
Topics: Chromatography, High Pressure Liquid; Circular Dichroism; Esomeprazole; Limit of Detection; Omeprazole; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Stereoisomerism | 2010 |
[Comparative study of esomeprazole and omeprazole using for initialism therapy for elderly-senile and young-adulthood patients with GERD].
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole | 2009 |
Nonpigmented fixed drug eruption induced by esomeprazole.
Topics: Drug Eruptions; Esomeprazole; Esophagitis, Peptic; Female; Humans; Middle Aged; Omeprazole; Proton Pump Inhibitors; Skin Pigmentation; Treatment Outcome | 2010 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Time Factors; Treatment Failure | 2010 |
Racemization of the gastrointestinal antisecretory chiral drug esomeprazole magnesium via the pyramidal inversion mechanism: A theoretical study.
Topics: Anti-Ulcer Agents; Esomeprazole; Gastrointestinal Tract; Models, Molecular; Molecular Conformation; Omeprazole; Quantum Theory; Stereoisomerism; Temperature; Thermodynamics | 2010 |
Esomeprazole for the treatment of peptic ulcer bleeding.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Esomeprazole; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Treatment Outcome | 2010 |
Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Topics: Arkansas; Cost Savings; Cost Sharing; Databases, Factual; Drug Costs; Drug Utilization Review; Esomeprazole; Health Benefit Plans, Employee; Health Expenditures; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Longitudinal Studies; Nonprescription Drugs; Omeprazole; Organizational Policy; Proton Pump Inhibitors; State Government | 2011 |
Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Assays; Esomeprazole; Female; Glucose Oxidase; Hypoglycemic Agents; Insulin; Male; Omeprazole; Peroxidase; Rabbits; Rats; Sulfonylurea Compounds | 2011 |
Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Esomeprazole; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Kinetics; Myocardial Contraction; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ventricular Function, Right | 2011 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Esophagitis, Peptic; Faith Healing; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Logistic Models; Los Angeles; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Racial Groups; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
Whole-cell oxidation of omeprazole sulfide to enantiopure esomeprazole with Lysinibacillus sp. B71.
Topics: Bacillus; Base Sequence; Bioreactors; Biotransformation; Chromatography, Thin Layer; Culture Media; DNA Primers; Esomeprazole; Hydrogen-Ion Concentration; Omeprazole; Oxidation-Reduction; Polymerase Chain Reaction; Stereoisomerism; Temperature | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian; Asian People; Blood Platelets; China; Clopidogrel; Drug Resistance; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; New York City; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Databases, Factual; Drug Interactions; Esomeprazole; Female; Herb-Drug Interactions; Hospitalization; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2011 |
The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon.
Topics: Age Factors; Algorithms; Anti-Ulcer Agents; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Omeprazole; Phenprocoumon; Predictive Value of Tests; Vitamin K | 2012 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Data Mining; Enzyme Inhibitors; Esomeprazole; Humans; Hypercalciuria; Nephrocalcinosis; Omeprazole; Renal Tubular Transport, Inborn Errors; United States; United States Food and Drug Administration | 2012 |
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
A positive event dependence model for self-controlled case series with applications in postmarketing surveillance.
Topics: Computer Simulation; Esomeprazole; Humans; Lactones; Models, Statistical; Myocardial Infarction; Omeprazole; Product Surveillance, Postmarketing; Research Design; Sulfones | 2013 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome | 2014 |
Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.
Topics: Bacillus megaterium; Bacterial Proteins; Crystallography, X-Ray; Cytochrome P-450 Enzyme System; Esomeprazole; Humans; NADPH-Ferrihemoprotein Reductase; Nuclear Magnetic Resonance, Biomolecular; Omeprazole; Oxidation-Reduction; Proton Pump Inhibitors; Substrate Specificity | 2014 |
Single enantiomer versus racemate: chiral distinction in the proton pump inhibitors omeprazole and esomeprazole.
Topics: Dimerization; Esomeprazole; Humans; Models, Chemical; Models, Molecular; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Water | 2014 |
The clopidogrel conundrum.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Interactions; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Topics: Age Factors; Bicarbonates; Buffers; Chemistry, Pharmaceutical; Esomeprazole; Geriatrics; Humans; Hydrogen-Ion Concentration; Kinetics; Lansoprazole; Omeprazole; Particle Size; Pediatrics; Phosphates; Proton Pump Inhibitors; Sodium Chloride; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical | 2015 |
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Young Adult | 2015 |
Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study.
Topics: Animals; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Esomeprazole; Limit of Detection; Liquid-Liquid Extraction; Male; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2016 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia.
Topics: Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2015 |
CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cytochrome P-450 CYP2C19; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Precision Medicine; Proton Pump Inhibitors; Reproducibility of Results; Young Adult | 2015 |
Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acenocoumarol; Aged; Aged, 80 and over; Anti-Ulcer Agents; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Esomeprazole; Female; Hospitalization; Hospitals, Teaching; Humans; International Normalized Ratio; Male; Omeprazole; Pantoprazole; Phenprocoumon | 2015 |
Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stereoisomerism | 2015 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.
Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Esomeprazole; Gene Expression Regulation; Humans; Interleukin-1beta; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Monocytes; Omeprazole; Peritonitis; Primary Cell Culture; Proton Pump Inhibitors; Shock, Septic; Signal Transduction; Survival Analysis; Thioglycolates; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Zymosan | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Proton pump inhibitors, purple gastric juice and peptic ulcer disease.
Topics: Aged, 80 and over; Endoscopy, Digestive System; Esomeprazole; Female; Gastric Juice; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2017 |
Influences of proton pump inhibitor on Helicobacter pylori adherence to the gastrointestinal cell lines.
Topics: Antibiotics, Antitubercular; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Adhesion; Caco-2 Cells; Esomeprazole; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rifampin; Time Factors | 2017 |
Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Asian People; China; Esomeprazole; Europe; Female; Health Status; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Secondary Prevention; Severity of Illness Index; Treatment Outcome; White People | 2017 |
Drug interaction: Clopidogrel and PPIs.
Topics: Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2017 |
High performance liquid chromatography with photo diode array for separation and analysis of naproxen and esomeprazole in presence of their chiral impurities: Enantiomeric purity determination in tablets.
Topics: 2-Propanol; Chromatography, High Pressure Liquid; Esomeprazole; Hexanes; Limit of Detection; Naproxen; Omeprazole; Reproducibility of Results; Stereoisomerism; Tablets; Trifluoroacetic Acid | 2017 |
Omeprazole-induced hallucinations. Not as rare as you might think.
Topics: Adult; Drug Substitution; Esomeprazole; Esophagitis, Peptic; Hallucinations; Hernia, Hiatal; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2018 |
A pilot study comparing the effect of orally administered esomeprazole and omeprazole on gastric fluid pH in horses.
Topics: Animals; Anti-Ulcer Agents; Esomeprazole; Horse Diseases; Horses; Hydrogen-Ion Concentration; Omeprazole; Pilot Projects; Random Allocation; Treatment Outcome | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors.
Topics: Aryldialkylphosphatase; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Risk Factors | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Ultra high performance liquid chromatography method development for separation of omeprazole and related substances on core-shell columns using a Quality by Design approach.
Topics: Chromatography, High Pressure Liquid; Esomeprazole; Omeprazole; Temperature | 2020 |
A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Voriconazole | 2020 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
Topics: Animals; Anti-Ulcer Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Cysteine Proteases; Esomeprazole; Female; Humans; Lung Neoplasms; Lysosomes; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Omeprazole; Xenograft Model Antitumor Assays | 2021 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Down-Regulation; Drug Interactions; Esomeprazole; Humans; Inflammation; Interleukin-6; Midazolam; Omeprazole | 2022 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015.
Topics: Aged; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2022 |
Solvent-dependent carbon dots for multifunctional sensing of temperature, pH, and proton pump inhibitors.
Topics: Carbon; Esomeprazole; Hydrogen-Ion Concentration; Omeprazole; Phloroglucinol; Proton Pump Inhibitors; Quantum Dots; Rabeprazole; Solvents; Temperature | 2022 |
Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.
Topics: Case-Control Studies; Esomeprazole; Hospitalization; Humans; Hyponatremia; Omeprazole; Proton Pump Inhibitors | 2023 |
In-vitro antibacterial activity of omeprazole and esomeprazole in combination with ciprofloxacin as an alternative to repositioning against ESKAPE pathogens and evaluation of the cleavage capacity of plasmid DNA.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA; Esomeprazole; Omeprazole; Plasmids; Proton Pump Inhibitors | 2023 |
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Hemorrhage; Humans; Omeprazole; Prasugrel Hydrochloride; United States | 2023 |
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Treatment Outcome | 2023 |